2026 Q3 Portfolio Activity
In 2026 Q3, Caligan Partners LP maintained a portfolio of 31 distinct positions. The most significant new addition was OBSIDIAN THERAPEUTICS INC, now representing 0.74% of the total fund value. They heavily accumulated shares in REVOLUTION MEDICINES INC, increasing the position by 679.1%. Conversely, Caligan Partners LP completely exited their position in XENON PHARMACEUTICALS INC.
Position History
hover any row below to update
Loading…
Total Positions
31
Quarter
2026 Q3
Top Holding
RVMD (24.6%)
Top 10 Concentration
78.9%
Turnover Rate
23.4%
Sector HHI
0.18
Items per page:
Showing 1-31 of 31
Caligan Partners LP Full Holdings List — 2026 Q3
| Stock | History | Sector / Type | Port % | Prev % | Rank / Prev | Conviction | Change | % Change | Influence | Shares | Mkt Value | Avg Cost | Price Held | 1st Owned | Source | Source Date | Date Reported | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
RVMD
REVOLUTION MEDI...
|
Healthcare | 24.64% | 17.28% |
#1
1
Prev: #2
|
7.0 |
—
|
no change | no change |
P
S
|
1,961,795 | $402,678,042 | 2025 Q1 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
LQDA
LIQUIDIA CORPOR...
|
Healthcare | 15.03% | 30.45% |
#2
1
Prev: #1
|
6.5 |
—
|
no change | no change |
P
S
|
8,118,892 | $245,677,672 | 2022 Q4 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
ABVX
ABIVAX SA
|
Healthcare | 9.44% | 9.77% |
#3
Prev: #3
|
5.8 |
—
|
no change | no change |
P
S
|
1,557,924 | $154,265,634 | 2024 Q4 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
PCVX
VAXCYTE INC
|
Healthcare | 7.62% | 5.99% |
#4
Prev: #4
|
4.5 |
—
|
no change | no change |
P
S
|
2,188,636 | $124,533,388 | 2025 Q4 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
EXEL
EXELIXIS INC
|
Healthcare | 5.55% | 3.98% |
#5
Prev: #5
|
3.7 |
—
|
no change | no change |
P
S
|
1,553,262 | $90,726,033 | 2023 Q1 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
TNGX
TANGO THERAPEUT...
|
Healthcare | 3.82% | 3.68% |
#6
Prev: #6
|
2.0 |
—
|
1,143 | 0.0% |
P
S
|
2,501,246 | $62,406,088 | 2025 Q4 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
ADMA
ADMA BIOLOGICS ...
|
Healthcare | 3.61% | 2.25% |
#7
2
Prev: #9
|
1.9 |
—
|
150,000 | 2.6% |
P
S
|
5,875,007 | $58,926,320 | 2022 Q4 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
IMCR
IMMUNOCORE HLDG...
|
Healthcare | 3.10% | 2.06% |
#8
4
Prev: #12
|
3.7 |
—
|
290,824 | 21.1% |
P
S
|
1,672,141 | $50,649,151 | 2026 Q2 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
AVTX
AVALO THERAPEUT...
|
Healthcare | 3.07% | 2.75% |
#9
2
Prev: #7
|
1.7 |
—
|
104,437 | 3.3% |
P
S
|
3,268,303 | $50,103,085 | 2025 Q3 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
LBRX
LB PHARMACEUTIC...
|
Healthcare | 3.04% | 2.20% |
#10
1
Prev: #11
|
1.7 |
—
|
71,551 | 5.0% |
P
S
|
1,509,621 | $49,621,242 | 2026 Q1 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
VRDN
VIRIDIAN THERAP...
|
Healthcare | 2.76% | 1.90% |
#11
2
Prev: #13
|
2.1 |
—
|
no change | no change |
P
S
|
2,193,981 | $45,174,069 | 2026 Q2 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
VOR
VOR BIOPHARMA I...
|
Healthcare | 2.25% | 1.67% |
#12
2
Prev: #14
|
1.9 |
—
|
no change | no change |
P
S
|
1,925,066 | $36,730,259 | 2025 Q4 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
IVA
INVENTIVA SA
|
Healthcare | 2.07% | 1.45% |
#13
3
Prev: #16
|
2.8 |
—
|
1,022,744 | 12.5% |
P
S
|
9,185,935 | $33,896,100 | 2025 Q4 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
IRD
OPUS GENETICS I...
|
Healthcare | 1.77% | 1.17% |
#14
5
Prev: #19
|
1.2 |
—
|
-116,112 | -1.9% |
P
S
|
5,960,972 | $28,851,104 | 2026 Q1 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
AURA
AURA BIOSCIENCE...
|
Healthcare | 1.76% | 1.44% |
#15
2
Prev: #17
|
2.7 |
—
|
292,005 | 6.8% |
P
S
|
4,590,253 | $28,826,789 | 2025 Q2 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
ANIK
ANIKA THERAPEUT...
|
Healthcare | 1.73% | 0.99% |
#16
4
Prev: #20
|
1.7 |
—
|
no change | no change |
P
S
|
1,435,130 | $28,214,656 | 2022 Q4 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
SABS
SAB BIOTHERAPEU...
|
Healthcare | 1.69% | 1.46% |
#17
2
Prev: #15
|
2.7 |
—
|
769,691 | 9.7% |
P
S
|
8,736,898 | $27,695,967 | 2026 Q1 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
SGMT
SAGIMET BIOSCIE...
|
Healthcare | 1.69% | 0.91% |
#18
3
Prev: #21
|
2.7 |
—
|
294,484 | 11.8% |
P
S
|
2,794,484 | $27,609,502 | 2026 Q2 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
SNSE
FAETH THERAPEUT...
|
Healthcare | 1.62% | 0.74% |
#19
4
Prev: #23
|
3.1 |
—
|
260,743 | 41.4% |
P
S
|
890,210 | $26,474,845 | 2026 Q1 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
TYRA
TYRA BIOSCIENCE...
|
Healthcare | 1.22% | 1.21% |
#20
2
Prev: #18
|
2.5 |
—
|
103,763 | 12.9% |
P
S
|
910,749 | $19,918,081 | 2025 Q1 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
OBX
OBSIDIAN THERAP...
|
Healthcare | 0.74% | — |
#21
Prev: #—
|
3.8 |
—
|
886,281 | — |
NEW
|
886,281 | $12,168,638 | 2026 Q3 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
EPRX
EUPRAXIA PHARMA...
|
Healthcare | 0.65% | — |
#22
Prev: #—
|
3.8 |
—
|
1,163,010 | — |
NEW
|
1,163,010 | $10,583,391 | 2026 Q3 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
ARTV
ARTIVA BIOTHERA...
|
Healthcare | 0.65% | 0.79% |
#23
1
Prev: #22
|
0.8 |
—
|
-255,068 | -14.7% |
P
S
|
1,481,043 | $10,545,026 | 2026 Q2 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
VRCA
VERRICA PHARMAC...
|
Healthcare | 0.27% | 0.27% |
#24
1
Prev: #25
|
1.1 |
—
|
no change | no change |
P
S
|
923,910 | $4,430,148 | 2023 Q3 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
N/A
TCGX ACQUISITIO...
|
|
Unknown | 0.15% | — |
#25
Prev: #—
|
3.6 |
—
|
200,000 | — |
NEW
|
200,000 | $2,502,000 | — | 13F Filing | 2026-09-30 | 2026-11-16 | ||
|
CLRB
CELLECTAR BIOSC...
|
Healthcare | 0.05% | 0.06% |
#26
2
Prev: #28
|
1.0 |
—
|
no change | no change |
P
S
|
469,998 | $864,796 | 2026 Q2 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
ADMA
CALL
ADMA BIOLOGICS ...
|
CALL Option | 0.00% | 0.12% |
Sold All 😨
(Was: #27) |
0.0 |
—
|
-300,000 | -100.0% |
CLOSED
|
— | $— | 2022 Q4 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
AGIO
CALL
AGIOS PHARMACEU...
|
CALL Option | 0.00% | 0.16% |
Sold All 😨
(Was: #26) |
0.0 |
—
|
-90,000 | -100.0% |
CLOSED
|
— | $— | 2022 Q4 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
MBX
MBX BIOSCIENCES...
|
Healthcare | 0.00% | 0.52% |
Sold All 😨
(Was: #24) |
0.0 |
—
|
-200,000 | -100.0% |
CLOSED
|
— | $— | 2026 Q1 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
RVMD
CALL
REVOLUTION MEDI...
|
CALL Option | 0.00% | 2.22% |
Sold All 😨
(Was: #10) |
0.0 |
—
|
-251,800 | -100.0% |
CLOSED
|
— | $— | 2025 Q1 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
XENE
XENON PHARMACEU...
|
Healthcare | 0.00% | 2.53% |
Sold All 😨
(Was: #8) |
0.0 |
—
|
-889,944 | -100.0% |
CLOSED
|
— | $— | 2025 Q3 | 13F Filing | 2026-09-30 | 2026-11-16 |
Showing 1-31 of 31 holdings